Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with > 1 year prior ibrutinib exposure
Munir, T Rawstron, A Brock, K Vicente, S Yates, F Bishop, R Cramp, S DeTute, R Dalal, S Webster, N
Munir, T
Rawstron, A
Brock, K
Vicente, S
Yates, F
Bishop, R
Cramp, S
DeTute, R
Dalal, S
Webster, N
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Munir T, Rawstron A, Brock K, Vicente S, Yates F, Bishop R, et al.Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with > 1 year prior ibrutinib exposure. Br J Haemat. 2019; 185:85-6.